{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:04:18Z","timestamp":1790697858572,"version":"4.1.0"},"reference-count":47,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:00:00Z","timestamp":1714003200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["R01 EY029594"],"award-info":[{"award-number":["R01 EY029594"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Stanley M. Truhlsen Family Foundation, Inc."}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of VitreoRetinal Diseases"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:p>Purpose: To evaluate clinical trials in the literature that focus on suprachoroidal drug delivery for the treatment of noninfectious uveitis and other posterior segment diseases. Methods: A synthesis of the literature was performed. Results: In 2021, suprachoroidal space triamcinolone acetonide, a corticosteroid delivery system used for the treatment of uveitic macular edema (ME), was approved by the US Food and Drug Administration. The drug-delivery system targets the suprachoroidal space using a microneedle-based device and has a favorable pharmacokinetic profile. Suprachoroidally administered investigational therapies have also been assessed in clinical trials for other posterior segment diseases, including diabetic ME, retinal vein occlusion, age-related macular degeneration, and choroidal melanoma. Conclusions: The safety and efficacy of suprachoroidal corticosteroid injections to treat uveitic ME have been shown in recent phase III clinical trials. Multiple programs are also investigating this modality of drug delivery for use in many other retinal and choroidal pathologies.<\/jats:p>","DOI":"10.1177\/24741264241246314","type":"journal-article","created":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T01:51:38Z","timestamp":1714096298000},"page":"401-409","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Suprachoroidal Drug Delivery for Macular Edema Associated With Noninfectious Uveitis"],"prefix":"10.1177","volume":"8","author":[{"given":"Ye","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, Stanley M. Truhlsen Eye Institute, University of Nebraska Medical Center, Omaha, NE, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlene","family":"Choo","sequence":"additional","affiliation":[{"name":"F.I. Proctor Foundation, University of California, San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelley","family":"Hancock","sequence":"additional","affiliation":[{"name":"Clearside Biomedical, Inc, Alpharetta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Ciulla","sequence":"additional","affiliation":[{"name":"Indiana University School of Medicine, Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7756-5091","authenticated-orcid":false,"given":"Charles C.","family":"Wykoff","sequence":"additional","affiliation":[{"name":"Retina Consultants of Texas, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica G.","family":"Shantha","sequence":"additional","affiliation":[{"name":"F.I. Proctor Foundation, University of California, San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Yeh","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, Stanley M. Truhlsen Eye Institute, University of Nebraska Medical Center, Omaha, NE, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,4,25]]},"reference":[{"key":"bibr1-24741264241246314","doi-asserted-by":"publisher","DOI":"10.37765\/ajmc.2022.89270"},{"key":"bibr2-24741264241246314","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S166092"},{"key":"bibr3-24741264241246314","unstructured":"Joszt L. Xipere for macular edema associated with uveitis launches in United States. AJMC. Published February 16, 2022. Accessed June 14, 2023. https:\/\/www.ajmc.com\/view\/xipere-for-macular-edema-associated-with-uveitis-launches-in-united-states"},{"key":"bibr4-24741264241246314","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2022.05.061"},{"key":"bibr5-24741264241246314","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2016.12.001"},{"key":"bibr6-24741264241246314","doi-asserted-by":"publisher","DOI":"10.1007\/s13346-020-00843-z"},{"key":"bibr7-24741264241246314","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2018.08.021"},{"key":"bibr8-24741264241246314","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-010-0271-y"},{"key":"bibr9-24741264241246314","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2006.05.045"},{"key":"bibr10-24741264241246314","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2011.07.027"},{"key":"bibr11-24741264241246314","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.04.001"},{"issue":"4","key":"bibr12-24741264241246314","volume":"2016","author":"Head K","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"bibr13-24741264241246314","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2007.11.002"},{"key":"bibr14-24741264241246314","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13070967"},{"key":"bibr15-24741264241246314","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2014.10.010"},{"key":"bibr16-24741264241246314","doi-asserted-by":"publisher","DOI":"10.1080\/17425247.2021.1867532"},{"key":"bibr17-24741264241246314","doi-asserted-by":"publisher","DOI":"10.3928\/23258160-20220617-01"},{"key":"bibr18-24741264241246314","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.12-9872"},{"issue":"13","key":"bibr19-24741264241246314","first-page":"5259","volume":"55","author":"Edelhauser HF","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"bibr20-24741264241246314","doi-asserted-by":"crossref","DOI":"10.1167\/iovs.05-0811","volume":"62","author":"Shah M","year":"2021","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bibr21-24741264241246314","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.5.6.14"},{"key":"bibr22-24741264241246314","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000002279"},{"key":"bibr23-24741264241246314","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.01.006"},{"key":"bibr24-24741264241246314","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2020-317560"},{"key":"bibr25-24741264241246314","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2020-318019"},{"key":"bibr26-24741264241246314","doi-asserted-by":"publisher","DOI":"10.1111\/ceo.14024"},{"key":"bibr27-24741264241246314","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2021.1954199"},{"key":"bibr28-24741264241246314","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2018.03.008"},{"key":"bibr29-24741264241246314","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2020.08.007"},{"key":"bibr30-24741264241246314","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2017.07.013"},{"key":"bibr31-24741264241246314","unstructured":"Clearside Biomedical, Inc. SAPPHIRE: a randomized, masked, controlled trial to study the safety and efficacy of suprachoroidal CLS-TA in conjunction with intravitreal aflibercept in subjects with retinal vein occlusion. clinicaltrials.gov. 2021. Accessed January 29, 2023. https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT02980874"},{"key":"bibr32-24741264241246314","unstructured":"Clearside Biomedical, Inc. A randomized, masked, controlled trial to study the safety and efficacy of suprachoroidal CLS-TA in combination with an intravitreal anti-VEGF agent in subjects with retinal vein occlusion. clinicaltrials.gov. 2021. Accessed January 29, 2023. https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT03203447"},{"key":"bibr33-24741264241246314","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.10.7.19"},{"key":"bibr34-24741264241246314","unstructured":"Clearside Biomedical, Inc. OASIS: open-label, dose-escalation, phase 1\/2a study of the safety and tolerability of suprachoroidally administered CLS-AX following intravitreal anti-VEGF therapy in subjects with neovascular age-related macular degeneration. clinicaltrials.gov. 2022. Accessed January 29, 2023. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04626128"},{"key":"bibr35-24741264241246314","unstructured":"Clearside Biomedical, Inc. Clearside biomedical announces positive 6-month results from OASIS extension study with suprachoroidal CLS-AX (axitinib injectable suspension) in wet AMD. Clearside Biomedical, Inc. IR Site. 2023. Accessed February 8, 2023. https:\/\/ir.clearsidebio.com\/news-releases\/news-release-details\/clearside-biomedical-announces-positive-6-month-results-oasis"},{"key":"bibr36-24741264241246314","unstructured":"Clearside Biomedical, Inc. Clearside biomedical announces plans for ODYSSEY phase 2b clinical trial of CLS-AX (axitinib injectable suspension) in wet AMD. Clearside Biomedical, Inc. IR Site. Published 2023. Accessed June 14, 2023. https:\/\/ir.clearsidebio.com\/news-releases\/news-release-details\/clearside-biomedical-announces-plans-odyssey-phase-2b-clinical"},{"key":"bibr37-24741264241246314","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0974"},{"key":"bibr38-24741264241246314","unstructured":"Aura Biosciences. Aura Biosciences announces positive interim phase 2 safety and efficacy data of belzupacap sarotalocan (Bel-sar) for the first-line treatment of patients with early-stage choroidal melanoma with suprachoroidal administration at the Macula Society 46th Annual Meeting. Aura Biosciences. Published 2023. Accessed June 14, 2023. https:\/\/ir.aurabiosciences.com\/news-releases\/news-release-details\/aura-biosciences-announces-positive-interim-phase-2-safety-and\/"},{"key":"bibr39-24741264241246314","unstructured":"National Library of Medicine. Study in subjects with small primary choroidal melanoma - tabular view. ClinicalTrials.gov. 2023. Accessed February 10, 2023. https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT03052127"},{"key":"bibr40-24741264241246314","unstructured":"Aura Biosciences. A phase 2 open-label, ascending single and repeat dose escalation trial of belzupacap sarotalocan (AU-011) via suprachoroidal administration in subjects with primary indeterminate lesions and small choroidal melanoma. clinicaltrials.gov. 2022. Accessed February 9, 2023. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04417530"},{"key":"bibr41-24741264241246314","unstructured":"Aura Biosciences. A phase 1B\/2 open-label, ascending single and repeat dose clinical trial designed to evaluate the safety and efficacy of light-activated AU-011 for the treatment of subjects with small primary choroidal melanoma. clinicaltrials.gov. 2022. Accessed February 9, 2023. https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT03052127"},{"key":"bibr42-24741264241246314","unstructured":"Aura Biosciences. Aura Biosciences announces interim phase 2 data evaluating suprachoroidal administration of belzupacap sarotalocan (AU-011) for the first-line treatment of patients with early-stage choroidal melanoma presented at AAO 2022. Aura Biosciences. 2022. Accessed February 10, 2023. https:\/\/ir.aurabiosciences.com\/news-releases\/news-release-details\/aura-biosciences-announces-interim-phase-2-data-evaluating\/"},{"key":"bibr43-24741264241246314","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2020.281"},{"key":"bibr44-24741264241246314","unstructured":"National Library of Medicine. RGX-314 gene therapy administered in the suprachoroidal space for participants with neovascular age-related macular degeneration (nAMD). 2023. Accessed February 8, 2023. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04514653"},{"key":"bibr45-24741264241246314","unstructured":"REGENXBIO Inc. REGENXBIO announces additional positive interim data from trials of RGX-314 for the treatment of wet AMD. REGENXBIO Inc. 2022. Accessed February 8, 2023. https:\/\/regenxbio.gcs-web.com\/news-releases\/news-release-details\/regenxbio-announces-additional-positive-interim-data-trials-rgx\/"},{"key":"bibr46-24741264241246314","unstructured":"REGENXBIO Inc. A phase 2, randomized, dose-escalation, observation-controlled study to evaluate the efficacy, safety, and tolerability of RGX-314 gene therapy delivered via a single suprachoroidal space (SCS) injections in participants with diabetic retinopathy (DR) without center involved-diabetic macular edema (CI-DME)(ALTITUDE). clinicaltrials.gov. 2022. Accessed February 9, 2023. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04567550"},{"key":"bibr47-24741264241246314","unstructured":"REGENXBIO Inc. REGENXBIO presents positive interim data from and the expansion of phase II ALTITUDE\n                      \u00ae\n                      trial of RGX-314 for the treatment of diabetic retinopathy using suprachoroidal delivery. Regenxbio Inc. Published 2023. Accessed June 14, 2023. https:\/\/regenxbio.gcs-web.com\/news-releases\/news-release-details\/regenxbio-presents-positive-interim-data-and-expansion-phase-ii\/"}],"container-title":["Journal of VitreoRetinal Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/24741264241246314","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/24741264241246314","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/24741264241246314","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:25:42Z","timestamp":1790695542000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/24741264241246314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,25]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1177\/24741264241246314"],"URL":"https:\/\/doi.org\/10.1177\/24741264241246314","relation":{},"ISSN":["2474-1264","2474-1272"],"issn-type":[{"value":"2474-1264","type":"print"},{"value":"2474-1272","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,25]]}}}